www.taro.com

Trademarks and Copyright© The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Taro to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions.

Investor FAQ
Q.When was Taro established?
A.The legal and commercial name of the company is Taro Pharmaceutical Industries Ltd. Taro was founded in Israel in 1950 and incorporated under the laws of the State of Israel in 1959. The Company expanded into Canada in 1984, and the U.S. in 1988. North America represents more than 90% of Taro’s sales.

Q.What is Taro's corporate address?
A.Taro Pharmaceutical Industries Ltd.
14 Hakitor Street
Haifa Bay 2624761 Israel

Q.What are the addresses of your major facilities?
A.

Taro Pharmaceutical Industries Ltd. (Taro Israel)
14 Hakitor Street
Haifa Bay 2624761 Israel

Taro Pharmaceuticals U.S.A., Inc. (Taro USA)
3 Skyline Drive
Hawthorne, NY 10532 USA

Taro Pharmaceuticals, Inc. (Taro Canada)
130 East Drive
Brampton, Ontario L6T 1C1, Canada

Taro Pharmaceuticals North America, Inc. (TNA)
190 Elgin Avenue
George Town, Grand Cayman KY 9005, Cayman islands


Q.Where are Taro’s shares listed?
A.Since March 22, 2012, our ordinary shares have been traded on the NYSE under the symbol “TARO.”

Q.How can I purchase shares of Taro stock?
A.Taro stock can be purchased through any brokerage firm. Taro does not have a Direct Stock Purchase Program.

Q.Who is Taro’s transfer agent?
A.American Stock Transfer
New York, NY USA
www.amstock.com
718-921-8210

Q.What can the transfer agent help me with?
A.Taro’s Transfer Agent can assist with any of the following issues:
  • Lost stock certificates
  • Clarification of number of shares owned
  • Transfer of certificates between individuals
  • Transfer of certificates to/from broker
  • Address changes
  • Other stock related matters

Q.Does Taro pay a dividend?
A.Taro has never paid cash dividends and we do not anticipate paying any cash dividends in the foreseeable future. We currently intend to retain our earnings to finance the development of our business, but such policy may change depending upon, among other things, our earnings, financial condition and capital requirements.

Q.Where can I find historical prices for Taro’s common stock?
A.Use the Historical Price Lookup feature under Stock Information within the Investor Relations section of this website. You can also obtain a Stock Quote or a Stock Chart, which provides stock prices and volume trends over selected periods, within the Stock Information section.

Q.How can I receive a hard copy of Taro's complete audited financial statements?
A.

The Annual Report on Form 20-F is also available on Taro’s website. (Click here)

Taro provides all shareholders, upon request, with a hard copy of our complete audited financial statements on Form 20-F- free of charge. Investor Relations Contact

Q.How can I receive investor materials as they are issued?
A.Click here to be added to our mailing list.

Q.How do I contact Taro Investor Relations?
A.Taro Pharmaceuticals U.S.A., Inc.
3 Skyline Drive
Hawthorne, NY 10532
Phone: (914) 345 9001
investorrelations@taro.com

Q.How can I receive a copy of your product list?
A.You can request a product list in the way that’s most convenient for you:
  • Use the online product list for the country you're interested in, then click on "Taro Products"
  • Call 1-888-TARO-USA
  • Write to us, c/o Taro Pharmaceuticals U.S.A., Inc., 3 Skyline Drive, Hawthorne, NY 10532, Attn: Marketing, Product list-Request

  • Q.What percentage of Taro does Sun Pharmaceuticals own?
    A.As of Nov. 17, 2017, Sun Pharmaceutical Industries Ltd., and its affiliates (“Sun’), control 73.6% of our outstanding ordinary shares and 100% of our founders’ shares; therefore, Sun controls 82.4% of the voting power in Taro.

    Q.Who do you consider as major competitors in your major markets?
    A.

    In Israel, we compete with Teva Pharmaceutical Industries Ltd., Perrigo Israel Pharmaceuticals Ltd., Dexcel Pharma Israel, and Rafa Laboratories Ltd., among others. In addition, many leading multinational companies, including Bayer AG, Eli Lilly and Company, Merck & Co., Inc. and Pfizer Inc., market their products in Israel.

    In the United States, we compete with branded pharmaceutical manufacturers such as Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Valeant Pharmaceuticals International, Inc. and Galderma Laboratories, LP., as well as with generic companies such as Teva Pharmaceuticals U.S.A., Mylan Inc., Perrigo Company PLC, Glenmark Generics, Inc., USA., PruGen Inc. and Sandoz Pharmaceuticals (the generics subsidiary of Novartis).

    In Canada, our competition includes Merck Canada Inc., Pfizer Canada Inc., Janssen Inc., Novartis Pharmaceuticals Canada Inc., GlaxoSmithKline Inc., Valeant Canada, AstraZeneca Canada, Johnson & Johnson Inc., Bayer Inc. and Bristol-Myers Squibb Canada. We also compete with other manufacturers of generic products, such as Apotex Inc., Teva Canada Limited, Mylan Pharmaceuticals ULC, Sandoz Canada Incorporated and Pharmascience Inc.


    Q.What is Taro’s fiscal year?
    A.Taro’s fiscal year runs from April 1 to March 31.

    Q.Can individual investors listen to the earnings conference call with analysts?
    A.Yes, Taro’s earnings conference calls are audio webcast live.  Transcripts of the recent earnings conference calls are on this website. (Click here)

    Q.Does Taro issue quarterly reports?
    A.Taro issues a quarterly Earnings Press Release and files these financial reports on Form 6-K with the SEC. You can find copies of recent reports on our website (Click here).

    Q.Who are the members of Taro’s Board of Directors?
    A.For a list of our Board members, (Click here).

    Terms of Use
      |  
    Privacy Statement
      |  
    Safe Harbor Statement